Heavy Buying Alert: Back-to-Back upper circuits & 52-week highs in this specialty chemicals & pharma stock; Do you own it?
The stock gave multibagger returns of 420 per cent from its 52-week low of Rs 58.20 per share.
Today, shares of Sudarshan Pharma Industries Ltd hit a 5 per cent upper circuit to an intraday high of Rs 302.60 per share from its previous closing of Rs 288.20 per share. The stock also made a new 52-week high of Rs 302.60 per share while its 52-week low is Rs 58.20 per share. The stock has been hitting back-to-back upper circuits & 52-week highs in the recent trading session. The company has not made any significant announcements of late. Hence, the rally in the share price could be driven purely by the market forces.
Sudarshan Pharma Industries Limited (SPIL), founded in 2008, is a Mumbai-based contract manufacturer of generic formulations. It operates in various segments, including specialty chemicals, intermediates, APIs, pharma and formulation generics, and bulk supply. SPIL sources and supplies pharmaceutical products to various institutions and healthcare organizations. Through its Vimac Healthcare division, it manufactures and sells its own branded products, with 56 out of 96 products registered under the "R" trademark. Additionally, SPIL provides contract manufacturing services for pharmaceutical formulations and medicines to well-known companies in India and institutional customers.
DSIJ’s ‘Micro Marvel' service recommends micro-cap stocks with the potential to grow multifold in long run. If this interests you, do download the service details here.
Sudarshan Pharma Industries Ltd has recently expanded its operations by incorporating a new subsidiary, Sudarshan Maven Pharma Private Limited. Sudarshan Pharma has taken a significant stake in Sudarshan Maven, subscribing to 70 per cent of its equity share capital. The newly formed subsidiary is primarily engaged in the manufacturing and development of various pharmaceutical products, including APIs, intermediates, and antibiotics. It also deals in healthcare products, Ayurvedic supplements, and medicinal preparations. Sudarshan Maven's acquisition aligns with Sudarshan Pharma's existing business and is expected to contribute to the growth and diversification of its operations in the chemical and pharmaceutical sectors.
The company has a market cap of Rs 728.23 crore and has delivered good profit growth of 37 per cent CAGR over the last 5 years. The stock gave multibagger returns of 420 per cent from its 52-week low of Rs 58.20 per share. Investors should keep an eye on this micro-cap stock.
Disclaimer: The article is for informational purposes only and not investment advice.
Also Read: Rs 1,20,000 Crore Order Book: Can This Defence Aircraft Company Be The Next Maharatna PSU After Oil India Ltd? Company Signed Rs 26,000 crore contract with MoD